ATNF Fundamental Analysis - 180 LIFE SCIENCES CORP

Fundamental Rating

We assign a fundamental rating of 1 out of 10 to ATNF. ATNF was compared to 557 industry peers in the Biotechnology industry. Both the profitability and financial health of ATNF have multiple concerns. ATNF is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ATNF has reported negative net income.

In the past year ATNF has reported a negative cash flow from operations.

In the past 5 years ATNF always reported negative net income.

ATNF had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

ATNF has a worse Return On Assets (-132.87%) than 83.48% of its industry peers.

ATNF's Return On Equity of -200.90% is on the low side compared to the rest of the industry. ATNF is outperformed by 68.22% of its industry peers.

		Industry Rank	Sector Rank
ROA	-132.87%
ROE	-200.9%
ROIC	N/A

ROA(3y)-229.08%

ROA(5y)-148.25%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ATNF does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, ATNF has more shares outstanding

The number of shares outstanding for ATNF has been increased compared to 5 years ago.

The debt/assets ratio for ATNF has been reduced compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -18.39, we must say that ATNF is in the distress zone and has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -18.39, ATNF is doing worse than 83.84% of the companies in the same industry.

A Debt/Equity ratio of 0.00 indicates that ATNF is not too dependend on debt financing.

The Debt to Equity ratio of ATNF (0.00) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-18.39

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

ATNF has a Current Ratio of 1.02. This is a normal value and indicates that ATNF is financially healthy and should not expect problems in meeting its short term obligations.

Looking at the Current ratio, with a value of 1.02, ATNF is doing worse than 88.15% of the companies in the same industry.

ATNF has a Quick Ratio of 1.02. This is a normal value and indicates that ATNF is financially healthy and should not expect problems in meeting its short term obligations.

ATNF has a worse Quick ratio (1.02) than 86.89% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.02
Quick Ratio	1.02

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 70.01% over the past year.

EPS 1Y (TTM)70.01%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%60.15%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

Based on estimates for the next years, ATNF will show a very strong growth in Revenue. The Revenue will grow by 80.13% on average per year.

EPS Next Y0%

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year54.15%

Revenue Next 2Y91.35%

Revenue Next 3Y90.65%

Revenue Next 5Y80.13%

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ATNF. In the last year negative earnings were reported.

Also next year ATNF is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ATNF does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

180 LIFE SCIENCES CORP

NASDAQ:ATNF (6/20/2025, 8:16:19 PM)

0.8642

-0.02 (-1.81%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)05-13 2025-05-13

Earnings (Next)08-11 2025-08-11

Inst Owners10.44%

Inst Owner Change-92.79%

Ins Owners13.02%

Ins Owner Change67.11%

Market Cap4.93M

Analysts82.86

Price TargetN/A

Short Float %2.02%

Short Ratio0.47

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	0.64
P/tB	58.92
EV/EBITDA	N/A

EPS(TTM)-12.46

EYN/A

EPS(NY)-3.06

Fwd EYN/A

FCF(TTM)-0.23

FCFYN/A

OCF(TTM)-0.23

OCFYN/A

SpS0

BVpS1.35

TBVpS0.01

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-132.87%
ROE	-200.9%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-229.08%

ROA(5y)-148.25%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score6

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.02
Quick Ratio	1.02
Altman-Z	-18.39

F-Score6

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)70.01%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%60.15%

EPS Next Y0%

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next Year54.15%

Revenue Next 2Y91.35%

Revenue Next 3Y90.65%

Revenue Next 5Y80.13%

EBIT growth 1Y38.62%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y90.66%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y90.66%

OCF growth 3YN/A

OCF growth 5YN/A

180 LIFE SCIENCES CORP (ATNF) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens